Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Other Non-Current Liabilities (2023 - 2025)

Vycor Medical has reported Other Non-Current Liabilities over the past 5 years, most recently at $3.7 million for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 10.9% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, up 10.9% year-over-year, with the annual reading at $3.7 million for FY2025, 10.9% up from the prior year.
  • Other Non-Current Liabilities was $3.7 million for Q4 2025 at Vycor Medical, roughly flat from $3.6 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $3.7 million in Q4 2025 and troughed at $2.8 million in Q1 2023.
  • The 3-year median for Other Non-Current Liabilities is $3.2 million (2024), against an average of $3.2 million.
  • Year-over-year, Other Non-Current Liabilities rose 13.53% in 2024 and then increased 9.77% in 2025.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $3.0 million in 2023, then increased by 11.46% to $3.3 million in 2024, then rose by 10.9% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Other Non-Current Liabilities are $3.7 million (Q4 2025), $3.6 million (Q3 2025), and $3.5 million (Q2 2025).